Product Pipeline

Scintilla Pharmaceuticals pipeline consists of two investigational product candidates spanning the interventional pain spectrum.

Product Indication Preclinical Phase I Phase II Phase III
SP-102 Lumbar Radiculopathy

100%

RTX Cancer Pain

100%

Product Indication Phase
SP-102 Lumbar Radiculopathy Phase 2
RTX Cancer Pain Phase 1
  • Near term clinical milestones
  • Worldwide commercial rights to all products
  • Strong proprietary platform

These products are investigational and as such, have not been approved by the FDA or any regulatory authority.